Preclinical in vivo modeling of pediatric sarcoma: promises and limitations

Pediatric sarcomas are an extremely heterogeneous group of genetically distinct diseases. Despite the increasing knowledge on their molecular makeup in recent years, true therapeutic advancements are largely lacking and prognosis often remains dim, particularly for relapsed and metastasized patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Imle, Roland (VerfasserIn) , Kommoss, Felix (VerfasserIn) , Banito, Ana (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 8 April 2021
In: Journal of Clinical Medicine
Year: 2021, Jahrgang: 10, Heft: 8, Pages: 1-27
ISSN:2077-0383
DOI:10.3390/jcm10081578
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/jcm10081578
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2077-0383/10/8/1578
Volltext
Verfasserangaben:Roland Imle, Felix K.F. Kommoss, and Ana Banito
Beschreibung
Zusammenfassung:Pediatric sarcomas are an extremely heterogeneous group of genetically distinct diseases. Despite the increasing knowledge on their molecular makeup in recent years, true therapeutic advancements are largely lacking and prognosis often remains dim, particularly for relapsed and metastasized patients. Since this is largely due to the lack of suitable model systems as a prerequisite to develop and assess novel therapeutics, we here review the available approaches to model sarcoma in vivo. We focused on genetically engineered and patient-derived mouse models, compared strengths and weaknesses, and finally explored possibilities and limitations to utilize these models to advance both biological understanding as well as clinical diagnosis and therapy.
Beschreibung:Gesehen am 09.06.2021
Beschreibung:Online Resource
ISSN:2077-0383
DOI:10.3390/jcm10081578